

ADVENTRX PHARMACEUTICALS INC  
Form 8-K  
May 03, 2010

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 8-K  
CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): May 3, 2010**

**ADVENTRX Pharmaceuticals, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation)

**001-32157**  
(Commission File Number)

**84-1318182**  
(IRS Employer Identification No.)

**6725 Mesa Ridge Road, Suite 100  
San Diego, CA 92121**

(Address of principal executive offices and zip code)

**Not applicable**

(Former name or former address if changed since last report)

Registrant's telephone number, including area code: **(858) 552-0866**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01 Entry into a Material Definitive Agreement.**

On April 29, 2010, ADVENTRX Pharmaceuticals, Inc. (the Company) entered into an engagement letter agreement with Rodman & Renshaw, LLC (the Placement Agent) pursuant to which the Placement Agent agreed to serve as exclusive placement agent for the Company on a reasonable best efforts basis in connection with a proposed offering by the Company of its securities.

On May 2, 2010, the Company entered into a securities purchase agreement with certain investors, pursuant to which the Company agreed to sell an aggregate of 19,217.13016 shares of its 2.19446320054018% Series F Convertible Preferred Stock (convertible preferred stock) and warrants to purchase up to an aggregate of 2,595,156 shares of its common stock (warrants). The convertible preferred stock and warrants will be sold in units, with each unit consisting of one share of convertible preferred stock, a Series A Common Stock warrant to purchase approximately 94.53 shares of common stock and a Series B Common Stock warrant to purchase approximately 40.51 shares of common stock. Each unit will be sold at a negotiated price of \$1,000. An aggregate of 7,785,468 shares of the Company's common stock are issuable upon conversion of the convertible preferred stock and exercise of the warrants.

Subject to certain ownership limitations, the convertible preferred stock will be convertible at the option of the holder at any time into shares of the Company's common stock at an effective conversion price of \$3.7025 per share, and will accrue a 2.19446320054018% dividend until May 6, 2020. In the event the convertible preferred stock is converted at any time prior to May 6, 2020, the Company will pay the holder of the converted convertible preferred stock an amount equal to the total dividend that would accrue on such convertible preferred stock, or approximately \$219.45 per \$1,000 stated value of convertible preferred stock converted, less dividends paid with respect to such converted convertible preferred stock before the relevant conversion date. The conversion price of the convertible preferred stock will be subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions. The convertible preferred stock will be subject to automatic conversion into shares of common stock upon the occurrence of a change in control of the Company and the Company may become obligated to redeem the convertible preferred stock upon the occurrence of certain triggering events, including the material breach of certain contractual obligations to the holders of the convertible preferred stock, the occurrence of a change in control of the Company, the occurrence of certain insolvency events relating to the Company or the failure of the Company's common stock to continue to be listed or quoted for trading on one or more specified United States securities exchanges.

Subject to certain ownership limitations, the Series A Common Stock warrants will be exercisable at any time after their date of issuance and on or before the 5-year anniversary of their initial exercise date at an exercise price of \$3.65 per share of common stock. Subject to certain ownership limitations, the Series B Common Stock warrants will be exercisable at any time after their date of issuance and on or before the date that is ten trading days after the 1-year anniversary of their initial exercise date, at an exercise price of \$3.65 per share of common stock. The exercise price of the warrants and, in some cases, the number of shares issuable upon exercise, are subject to adjustment in the case of stock splits, stock dividends, combinations of shares and similar recapitalization transactions.

The securities purchase agreement and the certificate of designation authorizing the convertible preferred stock include certain agreements and covenants for the benefit of the holders of the convertible preferred stock, including restrictions on the Company's ability to amend its certificate of incorporation and bylaws, pay cash dividends or distributions with respect to its common stock or other junior securities, repurchase shares of its common stock or other junior securities, issue additional equity securities for a period of 90 days after the closing of the transaction and incur indebtedness, and a requirement to use its reasonable best efforts to maintain the listing of its common stock on one or more specified United States securities exchanges.

The convertible preferred stock, the warrants and the shares of common stock underlying the convertible preferred stock and the warrants are being offered and will be issued and sold pursuant to the Company's effective shelf registration statement on Form S-3 (File No. 333-165691) and the related prospectus included therein and the prospectus supplement, dated May 2, 2010 and filed with the Securities and Exchange Commission on May 3, 2010 pursuant to Rule 424(b) under the Securities Act of 1933, as amended. The net proceeds to the Company from the offering, after deducting the placement agent's fees and the Company's estimated offering expenses, and after

deducting the Company's dividend and related payment obligations, and excluding the proceeds, if any, from the exercise of the warrants issued in the offering, are expected to be approximately \$13.4 million. The transaction is expected to close on May 6, 2010, subject to satisfaction of customary closing conditions. At the closing, approximately 22%, or approximately \$4.2 million, of the gross proceeds will be placed in an escrow account, which amount will be

---

released to make dividend payments and any make-whole payments payable to the holders of the convertible preferred stock.

A copy of the opinion of counsel to the Company relating to the legality of the issuance and sale of the shares of convertible preferred stock and warrants comprising the units and shares of common stock issuable upon conversion of the convertible preferred stock and exercise of the warrants is attached as Exhibit 5.1 hereto.

Pursuant to the terms of an engagement letter agreement with the Placement Agent, assuming the sale of all of the units in the offering, the Company will pay the Placement Agent a fee equal to approximately \$1,537,370. This amount represents 8.0% of the gross proceeds from the sale of the securities, of which \$201,780, or 13.125%, shall be paid to Caris & Company, the company selected by the Company to act as a non-exclusive financial advisor in connection with the financing.

The foregoing description of the terms of the certificate of designation of preferences, rights and limitations of the convertible preferred stock, the securities purchase agreement, the warrants and the engagement letter agreement are subject to, and qualified in their entirety by, such documents attached hereto as Exhibits 3.1, 4.1, 4.2 and 10.1, respectively, and incorporated herein by reference. A copy of the press release announcing the registered direct public offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.**

On May 3, 2010, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of 2.19446320054018% Series F Convertible Preferred Stock with the Secretary of State of the State of Delaware. The description of the certificate of designation and the convertible preferred stock contained in Item 1.01 above are incorporated herein by reference and are subject to, and qualified in their entirety by, the certificate of designation attached hereto as Exhibit 3.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

The list of exhibits called for by this Item is incorporated by reference to the Exhibit Index filed with this report.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ADVENTRX Pharmaceuticals, Inc.**

Dated: May 3, 2010

By: /s/ Patrick L. Keran  
Name: Patrick L. Keran  
Title: President and Chief Operating  
Officer

---

**Exhibit Index**

| <b>Exhibit No.</b> | <b>Description</b>   |
|--------------------|--|
| 3.1                | Certificate of Designation of Preferences, Rights and Limitations of 2.19446320054018% Series F Convertible Preferred Stock  |
| 4.1                | Form of Securities Purchase Agreement, dated May 2, 2010, by and between ADVENTRX Pharmaceuticals, Inc. and the purchaser(s) listed on the signature pages thereto |
| 4.2                | Form of Series ____ Common Stock Purchase Warrant  |
| 5.1                | Opinion of DLA Piper LLP (US)  |
| 10.1               | Engagement Letter Agreement, dated April 29, 2010, by and between ADVENTRX Pharmaceuticals, Inc. and Rodman & Renshaw, LLC   |
| 23.1               | Consent of DLA Piper LLP (US) (included in Exhibit 5.1)  |
| 99.1               | Press Release, dated May 3, 2010   |